Receptor News and Research

RSS

Laboratory test shows only 60% of COVID-19 patients develop protective antibodies

A laboratory test that has now been developed by a study group from MedUni Vienna is able to determine whether COVID-19 patients develop protective antibodies after having the disease.

5 Aug 2020

Avidity of binding responsible for cross-neutralization of SARS-CoV-1 and SARS-CoV-2

In a new study published on the preprint server bioRxiv researchers characterized the crystal structure of the antibody-SARS-CoV-2 RBD complex in an attempt to find the epitope and the mechanism that enables cross-neutralization.

5 Aug 2020

Embryos are susceptible to COVID-19 if mothers get sick, indicates study

Genes that are thought to play a role in how the SARS-CoV-2 virus infects our cells have been found to be active in embryos as early as during the second week of pregnancy, say scientists at the University of Cambridge and the California Institute of Technology (Caltech).

5 Aug 2020

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

De novo protein decoys that block SARS-CoV-2

Now, a new study published on the preprint server bioRxiv in August 2020 shows that computational design technology can be efficiently harnessed towards this end, producing new molecules to inhibit viral entry and replication.

5 Aug 2020

New computational model can help determine drug viability

About 50% of people who take the drug infliximab for inflammatory bowel diseases, such as Crohn's disease, end up becoming resistant or unresponsive to it.

5 Aug 2020

NCI gives 'exceptional' rating to Penn's Abramson Cancer Center

The National Cancer Institute has once again rated the Abramson Cancer Center of the University of Pennsylvania as "exceptional," the highest possible rating for an NCI-designated comprehensive cancer center.

4 Aug 2020

Decoy receptor neutralizes SARS-CoV-2 virus in tissue cultures

As the COVID-19 pandemic continues to spread, scientists and health care providers are seeking ways to keep the coronavirus from infecting tissues once they're exposed. A new study suggests luring the virus with a decoy - an engineered, free-floating receptor protein - binds the virus and blocks infection.

4 Aug 2020

Picomolar inhibitors to SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in August 2020 reports the development of mini-inhibitors based on computational design, that are suitable for such topical use.

4 Aug 2020

Novel mutation identified in SARS-CoV-2 spike protein from Sweden

Researchers from Sweden and Brazil have identified a novel mutation in a strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) obtained from a patient in Stockholm, Sweden, in late April.

4 Aug 2020

Yale researchers develop new mouse model to study SARS-CoV-2 infection

Researchers at Yale University School of Medicine have developed a new mouse model to study SARS-CoV-2 infection and disease and to accelerate testing of novel treatments and vaccines against the novel coronavirus.

4 Aug 2020

Researchers initiate multiple studies to identify coronavirus-related heart problems

COVID-19 is shown to impact the heart and, in some cases, have long-lasting cardiac effects. To discover the extent to which COVID-19 affects the heart, cardiologists and researchers with the University of Miami Miller School of Medicine have begun multiple studies.

4 Aug 2020

Membrane protein regulates epigenetic plasticity by mediating iron endocytosis

CNRS researchers at the Institut Curie have recently shown that cancer cells use a membrane protein that has been known for several decades to internalise iron.

3 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Novel short ACE2 isoform may influence SARS-CoV-2 susceptibility

A study led by researchers at the University of Southampton, UK, has identified a novel short isoform of the full-length receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain entry to host cells.

3 Aug 2020

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020